YIH
CHRS icon

Y-Intercept (HK)’s Coherus Oncology CHRS Stock Holding History

Y-Intercept (HK)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,591
Closed -$172K – 1406
2023
Q4 		$172K Buy
+51,591
New +$138K 0.02% 1029
2023
Q3 		– Sell
-27,023
Closed -$115K – 1113
2023
Q2 		$115K Buy
+27,023
New +$159K 0.01% 1055

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Y-Intercept (HK)'s CHRS Position: Q1 2024 in Review

Y-Intercept (HK) sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 51,591 shares — an estimated $172K sold.

Y-Intercept (HK) first reported a position in CHRS in Q2 2023 and held it in 2 quarters. The position peaked at $172K in Q4 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Y-Intercept (HK) reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 51,591 Coherus Oncology shares in Q1 2024, an estimated $172K.
  • Y-Intercept (HK) first reported a position in Coherus Oncology in Q2 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Coherus Oncology position peaked at $172K in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.